Introduction
Di abetes is associated with diminished quality of life,disabling complications, high health care costs, and reduced life expectancy. The International Diabetes Federation currently estimates that 285 million people are affected by diabetes globally. 1 Projected growth in diabetes burdens are being driven largely by transitioning sociodemographic, economic, and environmental circumstances and will be felt most notably in low-and middleincome countries (LMIC) that are experiencing these transitions rapidly.
For most chronic noncommunicable diseases such as diabetes, the current aggregated evidence from large trials supports combining positive lifestyle choices (appropriate nutritional choices, regular physical exercise, plus tobacco avoidance and/or cessation) [2] [3] [4] [5] [6] [7] [8] [9] with intensive and multifaceted risk-factor management [i.e., intensively controlling blood pressure (BP) and lipid levels together] [10] [11] [12] and preventative checks (e.g., annual eye, foot, and urine tests) to identify precursors of progression to complications [cardiovascular disease (CVD), retinopathy, nephropathy, neuropathy, peripheral arterial disease]. Despite robust trial evidence demonstrating efficacy of these measures to prevent and/or delay onset of these disabling and life-threatening complications, implementation of evidence-based interventions is far from optimal worldwide. [13] [14] [15] [16] [17] and trends) and may be enhanced to varying degrees through the addition of the following complementary functions: (1) link to pharmacies for automated prescription ordering, (2) automated decision support (e.g., reminders and therapeutic prompts), and/or (3) automated administrative processes (e.g., billing). 21 In particular, integrating decision-support tools with EMRs provides an opportunity to improve quality of care delivery by linking updated, aggregated, patient-specific data to evidence-based guidelines and computing tailored recommendations at the point of care. These enhancements may elevate care delivery in general practice settings, offsetting disparities between generalist and specialist diabetes care.
Although CDSSs have been shown to improve physician performance, the literature is equivocal with regard to patient outcomes. 28 Also, the evidence regarding the external validity (sustainability, cost-effectiveness, acceptability, and scalability) 29 of applying these HIT interventions in lowresource settings has not been established. 30 In this article, we review and synthesize the literature regarding combined EMR-CDSS tools for diabetes management. To make appropriate recommendations for LMIC settings, we also explore the parallel issues of costs and patient and provider perspectives on performance and implementation of HIT tools for clinical diabetes care.
Methods
We searched the MEDLINE electronic database (using PubMed) for published studies assessing EMR-CDSS for diabetes. We used medical subject heading terms related to diabetes ("diabetes mellitus") and computerized systems in clinical care ("medical records systems, computerized" or "decision-support systems, clinical" or "decision-support systems, management"). The search was limited to studies published in English and those related to humans. Up to November 30, 2010, our electronic search revealed 389 articles. Specific, standardized criteria were applied during review and selection of studies. We supplemented our search with manual searches of relevant articles.
To be included in this review, studies must have reported on the following:
• Adult or child populations with type 1 or 2 diabetes mellitus;
• Testing integrated EMR-CDSS tools for clinical diabetes care [defined as any "electronic or computerized medical record or registry with any enhanced functionalities (reminders, management prompts, automated prescriptions, self-care support, patient report generation, or provider feedback)"]; and
• Relevant outcomes, defined as processes of care (regularity of preventative visits and laboratory testing), self-monitoring, medication compliance, patient outcomes (biochemical results, satisfaction, health-related quality of life, costs, or complications), or practice-level considerations (coordination of care, patient-provider interactions).
Predefined exclusion criteria include publications that involved the following:
• Participants with gestational, secondary, or rare forms of diabetes;
• Studies describing methods or technology designs for upcoming/ongoing studies;
• Case studies and reviews regarding EMR-CDSS tools;
• Use of EMR-CDSS tools for conditions other than diabetes or in-patient hospital care; and
• Utilization of HIT and computerized systems for purposes other than direct clinical patient care (e.g., identification of at-risk individuals from databases).
Study designs such as randomized controlled trials (RCTs), quasi-experimental designs (pre-post studies, controlled or uncontrolled), observational studies, retrospective audits, and qualitative evaluations were deemed acceptable. There were no limits on setting and timing of study publications included.
Figure 1
shows the search and study sorting process that led to full-text reviews of 76 study publications and inclusion of 33 studies (26 reporting quantitative indicators and 7 recounting qualitative themes). Studies were most commonly excluded because of a lack of relevance to quality of care or HIT (126), not testing direct outcomes of EMR-CDSS tools (146), or inappropriate scope of HIT use or study type (review, editorial; 41).
Analysis
Quantitative and qualitative data were extracted from study publications by separate single reviewers, respectively. All relevant data were tabulated and synthesized for reporting. This study was not a comprehensive metaanalysis nor a systematic review. Although formal assess-ments of study quality are not presented, this narrative review broadly examines the characteristics of study interventions, study designs, analytical approaches, and cautiously reports effect sizes.
Results

Studies Reporting Quantitative Outcomes
Detailed descriptions of the interventions, designs, and outcomes of studies reporting predominantly clinical care process indicators or measures of metabolic control among patients can be found in 
Processes of Care and Clinical Outcomes
A total of 21 studies reported any clinical care process indicators [either proportions achieving process targets or mean number of biochemical (regular BP, lipid, glycemic control, or hemoglobin A1c [A1C] checks) and preventative examinations (annual foot, eye, urine examinations) or used process scoring] and reported either pre-and post-intervention or between-group (intensive and control) levels. Studies reported either proportions of participants achieving biochemical riskfactor control targets or the mean achieved risk-factor levels, with only 5 reporting neither. Improvements in process outcomes associated with EMR-CDSS implementation ranged from no difference to approximately 30% increases in percentage receiving annual A1C, BP, lipid, foot, urine, and eye examinations between groups or pre-and post-intervention. Changes in glycemic control varied from no difference to 1.8% point reduction from baseline (with varied reporting and levels of statistical significance). The vast majority of studies demonstrated A1C reductions in the order of 0.3-0.9% points over the duration of a year. Also, up to a 20% greater achievement of A1C targets was noted either post-intervention or in those allocated to intervention groups. During follow-up, BP control among participants ranged from no change up to either a 10/13 mm Hg reduction in BP from baseline or 22% increases in proportion of participants achieving BP goals. Low-density lipoprotein (LDL) reductions were observed up to 15 mg/dl along with 8-35% more participants achieving LDL <100 mg/dl. Very few studies reported changes in high-density lipoprotein, total cholesterol, or triglyceride levels.
Impacts: Clinical Endpoints and Costs
No studies reported hard clinical endpoints (CVD events, diabetes-related complications, or mortality). One single report tallied the number of hypoglycemic or hyperglycemic crises.
A total of five studies reported data related to costs and/or savings associated with interventions used, out of which one contained estimates from the mid 1990s. Themes that emerged from these studies are shown in Table 2 .
Studies Reporting Qualitative Assessments
Descriptions of qualitative assessments of EMR-CDSS use in clinical diabetes care are reported in Table 3 .
Of seven studies examined, four were United Statesbased, two were conducted in the United Kingdom, and one in Canada. Except for one mailed, self-administered questionnaire, all other studies were based in PHC clinics. Study types and methods included case studies (interviews, process observation, document review), pre-post evaluations (interviews and focus groups), and other onetime comparative observation or questionnaire studies.
Interventions with patient-accessed EMR-CDSS portals were well received by patients. Patients reported feeling that their concerns were valued, feeling empowered (tracking laboratory values themselves), and benefiting from more provider attention and feedback, resulting in enhanced security about their health. Frustrations included difficulties with HIT and not receiving prompt responses from providers, as well as difficulties fitting programs into daily activities. Moreover, patient-accessed EMR-CDSS was associated with increased Web-message communications but no fewer patient visits or phone calls.
Table 2. Themes Emerging from Studies Reporting Cost Data
• Initial resource inputs to implement EMR-CDSS and associated disruptions impose high upfront costs.
• Longer-term use of EMR-CDSS may be associated with cost savings (reduced staff plus infrastructure needs) 48 or increased costs for complementary services (e.g., NCMs used average of 4 h per week to update patient care plans based on CDSS prompts). 37 • EMR-CDSS may contribute to decreased health service utilization (6.6% less outpatient and 23% less specialist visits with 17% less hospital admissions and 10% shorter in-patient stays reported in a multifaceted quality improvement strategy using EMR-CDSS) 49 and costs ($288 lower outpatient costs and $2311 lower overall costs, despite increased short-term pharmacy costs where participants adhere to regimen-intensifying prompts and end up purchasing more therapies and services). 33 Table 3 .
Characteristics of Studies Included in Qualitative (Including Mixed Methods) Study Review a
First author, country, No difference between 2 groups for time-space analysis, because either task could only be performed at the same time/ same place or different time/ same place (i.e., during and after patient visit at clinic). Patterns in hierarchical; goals, operators, methods, selection; and work flow analyses generally highlighted benefits of EMR versus paper records: standardized template structure with prompts, improved legibility, accessible remotely, data easily aggregated and analyzed; overall less time to use EMR with exception of novice users.
In an integrated clinical information system, EMRs help nurse documentation by decreasing redundancy, improving accuracy, and accessibility to other team members. Thompson, 62 Ireland ( 
Outcomes
Almost all studies reported key performance indicators that are accepted, evidence-based indicators reflecting care quality. [64] [65] [66] However, differences in reporting (percentage achieving process or control targets versus mean levels) prevented an aggregated quantitative data synthesis. The lack of studies reporting hard clinical endpoints most likely reflects insufficient sample sizes or duration of follow-up observed. Also, the lack of estimates of anticipated reductions in complications also explains the dearth of cost-effectiveness or cost-savings assessments.
On balance, among the studies reviewed, there were more consistent associations between EMR-CDSS adoption and improvements in clinical care processes than improved risk-factor control, consistent with a previous review of computerized interventions for diabetes care. 67 Most authors acknowledge that improved processes do not necessarily equate with reduced cardiometabolic risk. The studies reviewed allude to improvements in health service utilization and risk-factor control among those with poorer baseline risk profiles, suggesting that quality improvement interventions may have greater benefit where there is still room for improvement. Conversely, in systems where guideline adherence is near optimal, further improvements are not observed with EMR-CDSS interventions. 47, 68 Lastly, a third of studies meeting inclusion criteria did not report both care process measures and laboratory outcomes, which highlights a need for standard evaluation metrics to compare HIT interventions and assess key implementation and maintenance factors (e.g., cost, reach, implementation). 25
Analysis of Studies
Study design has a profound bearing on inferences that can be derived from research data. In particular, the studies in this review represent a mix of designs: uncontrolled pre-post studies and controlled trials with groups not receiving the intervention also experiencing process and control improvements. Taken together, these points allude to an overestimated effect size associated with the core intervention because these changes could conceivably be related to general improvements in awareness and care delivery over time. However, these criticisms may be counterbalanced by dilution of the intervention's effects where contamination was present (i.e., minimizing the aggregate differences observed between intensive and control groups because of contact between individuals in each arm). Also, individual effect sizes may be underestimates when derived from study Outpatient providers adopting clinic-based EMR-CDSS tools found improved efficiency and standardization of patient care processes over paper records and better informational continuity among and between providers (improving care coordination overall). Difficulties included differences in provider opinions regarding patient needs, conflicting role expectations, and communication gaps where information was not properly documented or shared. One study highlighted poor patient-provider interactions during visits on account of EMR-CDSS prompts making consultations mechanical and reducing patient-centeredness.
Discussion
This review reveals a number of key themes regarding the impact and performance of EMR-CDSS for diabetes and its applicability in LMICs. However, it is important to consider the limitations of this review when interpreting these findings. First, this compilation of studies includes vastly heterogeneous study designs, interventions, analytical methods, outcome indicators, and reporting. Second, the studies included were conducted exclusively in North America and Western Europe and may not offer generalizability for LMICs. Finally, searches were limited to a single database, which may have decreased the yield of relevant publications. To counteract this, we applied a comprehensive search strategy, utilized the leading medical literature database, and supplemented findings with manually searched articles.
Scope of Interventions
In this evaluation of computerized systems to support clinical decision-making, the authors noted that adoption of EMR-CDSS was associated with decreased interclinic or interprovider variability in processes and outcomes. Studies with multifaceted clinical care strategies [NCMs, workflow changes, enabling tools (patient information sheets, algorithms), financial incentives] had noticeably larger quantitative and qualitative effect sizes than those using isolated interventions, and we postulate that these better outcomes are related to targeting multiple levels (patients and providers). Our findings were consistent with other studies and guidelines that support structured, multifaceted diabetes management. 63, 64 The independent effects associated with each component intervention are unknown, as studies reviewed did not disaggregate the multifaceted interventions. In addition, decision-support tools with a greater number of features, interactive aspects, and patient-accessible portals were also associated with better outcomes.
populations in cluster RCTs, as randomization is at the clinic level while outcomes are measured for individual participants.
The generalizability that can be drawn from these findings is strongly associated with selection of participating individuals and/or clinics. Participants in all but one study (with type 1 diabetes patients) had mean age between 55 and 65 years, were predominantly of non-Hispanic White origin, and generally represented populations with access to health services and technology (insured, educated, regular computer/Internet users). Also, practitioners in these studies were more motivated (practices self-selected into some studies); other studies only analyzed data from participants with sufficient followups (isolating those who exhibit high compliance); and very few studies employed intention-to-treat analyses or reported loss-to-follow-up. Also, performance-based financial incentives used in some studies may encourage both positive and negative provider behaviors-either enhancing care practices for the duration that incentives are available or, alternatively, "selecting" patients with more favorable profiles to accrue more compensation. Other reviews on HIT in diabetes care have found similar limitations. 67, 69 Lastly, some authors skeptically note that the effects observed may simply reflect better documentation by providers, with no real improvement in processes; however, this critique does not account for real observed reductions in risk-factor levels.
Applicability to Low-and Middle-Income Country Settings
Considering the escalating diabetes burden and suboptimal adherence to management guidelines globally, 13, 15, [70] [71] [72] there are several areas where EMR-CDSS implementation may provide value in LMICs: 21, 28, 73 1. Structuring services and standardizing care processes (e.g., standard patient visit record format);
2. Emphasis on comprehensive multifactorial risk reduction (e.g., guideline-based patient-tailored prompts to physicians to consider all risks and/or intensify treatments);
3. Enhancing continuity (access to complete current and past patient data) and integration of clinical, diagnostic, and therapeutic information (e.g., medication history, drug interactions, allergies) among different providers in different settings, potentially reducing unnecessary costs of repeated diagnostic examinations;
4. Empowering patients (e.g., accessible health information resources and computerized reminders for follow-ups); and 5. Computerized administration of processes (e.g., billing, scheduling).
As in previous reviews of general and diabetes-specific utilization of HIT, our review also found that most published research has occurred in high-resource settings. 25, 74, 75 However, experience from diabetes clinical trials conducted in LMICs (e.g., ADVANCE trial in India) show similar outcomes as high-income country trials.
As such, extrapolation of high-income setting findings to LMIC settings seems reasonable, provided that there is understanding of the local context.
Low-and middle-income countries face major cost and organizational challenges-health care systems are complex with convoluted financing mechanics and systemic frailties (e.g., deficiencies of structure, referral linkages, and trained manpower). In these contexts, implementing and maintaining HIT interventions represents high capital cost and delayed returns (although this may not be the case for private practices). Some LMIC regions may also have inadequate informatics-trained human resources to design, implement, and maintain such systems. 30 Poor infrastructure (e.g., unreliable power supply and high-speed Internet connections), scarce HIT literacy, and culture-specific customs and perceptions regarding health and illness (e.g., it is unclear whether people in some settings will be amenable to undertaking intensive and costly treatment regimens to manage diabetes, a largely asymptomatic condition until onset of severe complications) may all impede adoption of HIT. 76 Equally, care prompts need not always be intensive. Trials have shown that elderly patients with multiple comorbidities may not tolerate such therapeutic changes. 77 The challenge in LMICs, therefore, is in the adaptation of HIT such that there is a balance between standardized, generic prompts and physician flexibility/ discretion to make decisions that are most suitable for individual patients.
General considerations, even for high-resource settings, must include provisions to address privacy and/or security breaches associated with using HIT, maintaining HIT content, developing organizational/technical capabilities for managing HIT, and incorporating technologies seamlessly into clinic workflow to ensure communication and coordination of care without sacrificing patient focus. 75, [78] [79] [80] There are successful examples of EMR-CDSS utilization and health informatics capacity-building in LMICs, mostly for conditions other than diabetes. Examples can be found in sub-Saharan African countries 81 (in particular Kenya, 82, 83 Cameroon, 84 Mozambique, 85 Rwanda, 86, 87 Uganda, and Malawi 88 ) as well as Peru, 89 Haiti, 90 Brazil, 89 Indonesia, 91 and India. 92 There may also be others that were not found in the mainstream academic literature. 30, 89, 93, 94 For example, a 2010 conference abstract describes a diabetes telemanagement system in Kerala, India, that integrates mobile phone and information technology tools and shows promise in enhancing self-management of blood glucose. 93 With an enabling environment, implementing and sustaining EMR-CDSS in LMICs is possible 94 and could have tangible benefits for diabetes care. 95 In fact, similar to the current ubiquitous use of cell phone technology in lieu of landline telephone services, EMR-CDSS tools offer opportunities to leapfrog many infrastructural deficits in LMICs. 96, 97 Systematic reviews of diabetes management highlight the utility of HIT for improving patient care in the context of an integrated model. 93, 98 This is a key point that also emerged from our findings-organizing and delivering care for people with diabetes and other chronic diseases potentially requires more than just HIT. Complementary personnel or workflow changes are "enabling"-they have a significant role in motivating patient self-management, augmenting the effectiveness of EMR-CDSS tools. From our experiences in India where physicians indicate preference for paper-based consultation records, auxiliary health personnel offer a complementary role, adopting responsibility for data entry and managing software applications, freeing physicians of these duties, but also prompting physicians with computer-generated recommendation printouts.
Scalability and sustainability of these HIT interventions, which are still considered cost intensive, will depend on accumulation of more evidence accounting for health care delivery design, which varies across and within LMICs. For example, large nationalized health systems or insurance-based health care delivery schemes focus on metrics evaluating population-level benefits (reduction in complications, hospitalizations, and mortality); meanwhile, individuals paying out-of-pocket for enhanced technologybased care at private providers will evaluate tradeoffs differently. In either case, potential models of care need to be rigorously tested in LMIC settings, using appropriate study designs and factoring in appropriate duration of follow-up, minimization of biases, and cost-effectiveness evaluations. 99 Lastly, generic HIT tools may not be appropriate for heterogeneous settings, so customizing tools to suit context-specific cultural variation, physician practices, and organizational norms may enhance adoption and implementation, 100 while assessments of patient acceptability may identify the key features that promote successful self-care adherence.
Conclusions
Our review is based on studies among populations in fundamentally different countries and contexts than the range of cultures, settings, and circumstances that are pervasive across all LMICs. Broadly, EMR-CDSS offers important process benefits (accountability, reduced fragmentation) at the provider and clinic level, with modest improvements in terms of risk-factor control and acceptability among patients. Although models of care centered on EMR-CDSS may be replicable in LMIC settings, we recommend exercising caution and considering appropriate customization of solutions to fit contexts. For example, although our review points to using fully functional, interactive, and patient-accessible EMR-CDSS, it is not clear from these studies what level of functionality will be acceptable or even accessible by providers and patients in LMICs. We therefore advocate testing customized interventions that can be easily integrated without major infrastructural overhaul. Also, due to the "digital divide" (whereby access to Internet and computer technology is limited to highest socioeconomic strata patients), we recommend complementary interventions in the form of trained nonphysician health workers to facilitate clinical care instead of patientaccessed portals for patient feedback.
We described the quality of studies and key characteristics that differentiate the interventions in these studies with a view to helping readers draw appropriate inferences from this evidence regarding technical efficiency of intervention delivery as well as identifying key gaps in the evidence accumulated to date. Although we reiterate the frailty of extrapolating from studies conducted entirely in high-income country settings, our hope is that this piece will have macrolevel benefits by stimulating greater investments in translation research of scalable strategies for high-quality diabetes care in LMICs.
